AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

Recruitingn/aAges 18 Years - 50 YearsAllLeiden University Medical Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * MCDA twin pregnancy * Diagnosis of sFGR before 28+0 weeks of GA (independent of Doppler flows) * Pregnant woman โ‰ฅ 18 years and able to consent * Partner (who has (future) parental responsibility - if applicable) โ‰ฅ 18 years and able to consent * Written informed consent of both parents (if applicable) for participation in the longitudinal follow-up until 2 years after birth) Exclusion Criteria: * The presence of lethal anomalies (one or both fetuses) * Multiple pregnancy higher order than twins; * TTTS/TAPS present at moment of sFGR diagnosis.
๐Ÿ’Š

What it tests

  • Ultrasound
๐Ÿ“

Where

6 sites
Boston Children's Hospital
Boston, United States
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Mount Sinai Hospital
Toronto, Canada
Leiden University Medical Center
Leiden, Netherlands
BCNatal
Barcelona, Spain
Karolinska University Hospital
Stockholm, Sweden
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy